Full Length Research Paper
References
Ako-Nai AK, Ikem IC, Akinloye OO, Aboderin, Ikem R, Kassim O (2006). Characterization of bacterial isolates from diabetic foot infections in Ile-Ife, Southwestern Nigeria. Foot 16(3): 158-164. Crossref |
||||
Bamberger DM, Daus GP, Gerding GN (1987).Osteomyelitis in the feet of diabetic patients. Long-term results, prognostic factors, and the role of antimicrobial and surgical therapy. Am. J. Med. 83(4): 653-660. Crossref |
||||
Bergey DH, Holt JG (1994). Bergey's manual of determinative bacteriology. Baltimore, Williams & Wilkins. | ||||
Birnboim HC, Doly J (1979).A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucleic Acids Res. 7(6):1513-1523. Crossref |
||||
Bonnet R (2004).Growing Group of Extended-Spectrum β-Lactamases: the CTX-M Enzymes. Antimicrob. Agents Chemother. 48(1):1-14. Crossref |
||||
Bonnet RC, Dutour JL, Sampaio MC, Chanal CD, Sirot D, Labia RJ, Sirot J (2001). Novel cefotaximase (CTX-M-16) with Increased catalytic efficiency due to substitution Asp-240→Gly. Antimicrob. Agents Chemother. 45(8):2269-2275. Crossref |
||||
Bradford PA (2001). Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat. Clin. Microbiol. Rev. 14(4):933-951. Crossref |
||||
Bush K, Jacoby GA, Medeiros AA (1995).A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39(6):1211-1233. Crossref |
||||
Chincholikar D, Pal R (2002). Study of fungal and bacterial infections of the diabetic foot. Indian J. Pathol. Microbiol. 45(1):15-22. Pubmed |
||||
Citron DM, Goldstein JC, Merriam CV, Lipsky BA, Abramson MA (2007). Bacteriology of Moderate-to-Severe Diabetic Foot Infections and In Vitro Activity of Antimicrobial Agents. J. Clin. Microbiol. 45(9):2819-2828. Crossref |
||||
Clinical and Laboratory Standards Institute (CLSI) (2010). Performance standards for antimicrobial susceptibility testing; twentieth informational supplement CLSI document M100-S20, Clinical and Laboratory Standards Institute, Wayne, PA. | ||||
Clinical and Laboratory Standards Institute (CLSI) (2011). Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement. CLSI document M100-S21, Clinical and Laboratory Standards Institute, Wayne, PA. | ||||
Dezfulian A, Salehian MT, Amini V, Dabiri H, Azimi Rad M, Aslani MM, Zali MR (2011). Bacteriological study of diabetic foot infections in an Iranian hospital. Iran Red Crescent Med. J. 13(8):590-591. Pubmed |
||||
Edmonds M (2006).Diabetic foot ulcers: practical treatment recommendations. Drugs 66(7):913-929. Crossref |
||||
Gadepalli R, Dhawan B, Sreenivas V, Kapil A, Ammini AC, Chaudhry R (2006).A Clinico-microbiological Study of Diabetic Foot Ulcers in an Indian Tertiary Care Hospital. Diabetes Care 29(8):1727-1732. Crossref |
||||
Gniadkowski M (2008).Evolution of extended-spectrum beta-lactamases by mutation. Clin. Microbiol. Infect. 14 Suppl. 1:11-32. Crossref |
||||
Gniadkowski M, Schneider I, Jungwirth R, Hryniewicz, W, Bauernfeind A (1998). Ceftazidime-resistant Enterobacteriaceae isolates from three polish hospitals: Identification of three novel TEM- and SHV-5- Type extended-spectrum β-lactamases. Antimicrob. Agents Chemother. 42(3):514-520. Pubmed |
||||
Hanahan D (1983).Studies on transformation of Escherichia coli with plasmids. J. Mol. Biol. 166(4):557-580. Crossref |
||||
Hartemann-Heurtier A, Marty L, Ha Van G, Grimaldi A (2000). Role of antibiotic therapy in diabetic foot management. Diabetes Metab. 26(3):219-224. Pubmed |
||||
Hatipoglu M, Mutluoglu M, Uzun G, Karabacak E, Turhan V, LipskyBA (2014) .The microbiologic profile of diabetic foot infections in Turkey: a 20-year systematic review: diabetic foot infections in Turkey. Eur. J. Clin. Microbiol. Infect. Dis. 33(6):871-878. Crossref |
||||
Hobizal KB, Wukich DK (2012). Diabetic foot infections: current concept review. Diabet. Foot Ankle 3. | ||||
Jacoby GA, Sutton L (1991).Properties of plasmids responsible for production of extended-spectrum beta-lactamases. Antimicrob. Agents Chemother. 35(1):164-169. Crossref |
||||
Jarlier V, Nicolas MH, Fournier G, Philippon A (1988). Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev. Infect. Dis. 10(4):867-878. Crossref |
||||
Jiang HX, Tang D, Liu YH, Zhang XH, Zeng ZL, Xu L, Hawkey PM (2012).Prevalence and characteristics of beta-lactamase and plasmid-mediated quinolone resistance genes in Escherichia coli isolated from farmed fish in China. J. Antimicrob. Chemother. 67(10):2350-2353. Crossref |
||||
Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, Tan JS (2006).Diagnosis and treatment of diabetic foot infections. Plast. Reconstr. Surg. 117(7 Suppl.): 212S-238S. Crossref |
||||
Mendes JJ, Marques-Costa A, Vilela C, Neves J, Candeias N, Cavaco-Silva P, Melo-Cristino J (2012). Clinical and bacteriological survey of diabetic foot infections in Lisbon. Diabetes Res. Clin. Pract. 95(1):153-161. Crossref |
||||
Motta RN, Oliveira MM, Magalhaes PS, Dias AM, Aragao LP, Forti AC, Carvalho CB (2003).Plasmid-mediated extended-spectrum beta-lactamase-producing strains of Enterobacteriaceae isolated from diabetes foot infections in a Brazilian diabetic center. Braz. J. Infect. Dis. 7(2):129-134. Crossref |
||||
Omar NS, El-Nahas MR, J. Gray J (2008).Novel antibiotics for the management of diabetic foot infections. Int. J. Antimicrob. Agents 31(5):411-419. Crossref |
||||
Paul S, Barai L, Jahan A (2009).A bacteriological study of diabetic foot infection in an urban tertiary care hospital of Dhaka city. Ibrahim Med. Coll. J. 3(2):50-54. | ||||
Poirel LR, Bonnin RA, Nordmann P (2012).Genetic support and diversity of acquired extended-spectrum β-lactamases in Gram-negative rods. Infect. Genet. Evol. 12(5):883-893 Crossref |
||||
Ramani A, Ramani R, Shivananda PG, Kundaje GN (1991). Bacteriology of diabetic foot ulcers. Indian J. Pathol. Microbiol. 34(2): 81-87. Pubmed |
||||
Rasheed JK, Jay C, Metchock B, Berkowitz F, Weigel F, Crellin J, Tenover FC (1997). Evolution of extended-spectrum beta-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia. Antimicrob. Agents Chemother. 41(3):647-653. Pubmed |
||||
Sambrook J, Russell DW (2001). Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press. | ||||
Staden R (1996).The Staden sequence analysis package. Mol. Biotechnol. 5(3):233-241. Crossref |
||||
Varaiya AY, Dogra JD, Kulkarni MH, Bhalekar PN (2008).Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in diabetic foot infections. Indian J. Pathol. Microbiol. 51(3):370-372. Crossref |
||||
Whiting DR, Guariguata L, Weil C, Shaw J (2011).IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res. Clin. Pract. 94(3):311-321. Crossref |
||||
Zubair M, Malik A, Ahmad J (2011).Clinico-microbiological study and antimicrobial drug resistance profile of diabetic foot infections in North India. Foot (Edinb) 21(1):6-14. Crossref |
||||
Zubair M, Malik A, Ahmad J (2012).Study of plasmid-mediated extended-spectrum beta-lactamase-producing strains of enterobacteriaceae, isolated from diabetic foot infections in a North Indian tertiary-care hospital. Diabetes Technol. Ther. 14(4):315-324. Crossref |
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0